All In Biotech

Drug Trial Radar · NCT04168385

MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study

MRX-800: A Long-Term Safety Study of Maralixibat, an Apical Sodium Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study

Last checked: Nov 20, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

52

Actual

Start

Jan 16, 2020

Primary completion

Sep 4, 2024

Study completion Sep 4, 2024

Sponsor

Lead sponsor
Mirum Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Nov 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the long-term safety of maralixibat (MRX) in subjects with cholestatic liver disease including, but not limited to, Alagille Syndrome (ALGS), Progressive Familial Intrahepatic Cholestasis (PFIC) and Biliary Atresia.

Conditions

  • Cholestatic Liver Disease

Interventions

  • MaralixibatDrug

    Maralixibat chloride oral solution orally twice daily (up to 1200\* mcg/kg/day), and according to indication. \*equivalent to 1140 mcg/kg/day maralixibat

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: From informed consent through approximately 4.5 years, including 30 days after last dose.

Locations

17 sites in 8 countries. Site status is shown where the registry gives one.

  • Children'S Hospital Los Angeles

    Los Angeles, California

  • Riley Hospital For Children

    Indianapolis, Indiana

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Children Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • Baylor College of Medicine/Texas Children's Hospital

    Houston, Texas

  • Seattle Children's Hospital

    Seattle, Washington

  • Children's Hospital Westmead

    Westmead, New South Wales, Australia

  • The Royal Children'S Hospital Melbourne

    Parkville, Victoria, Australia

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Hospital for Sick Children

    Toronto, Canada

  • Hopital Necker-Enfants Malades

    Paris, France

  • Hopital Kremlin Bicetre

    Paris, France

  • The Children's Memorial Health Institute

    Warsaw, Poland

  • Hospital Universitario La Paz- Hospital Materno Infantil

    Madrid, Spain

  • Birmingham Children's Hospital

    Birmingham, United Kingdom

  • Leeds Teaching Hospital NHS Trust

    Leeds, United Kingdom

  • Paediatric Liver Center, Kings College Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.